期刊文献+

手霉素对白血病干细胞和骨髓干细胞的细胞毒作用

Cytotoxic effect of manumycin on leukemic and myeloid stem cells
下载PDF
导出
摘要 目的探讨手霉素对白血病干细胞(LSC)的细胞毒作用。方法采用MTT法检测手霉素对LSC的细胞增殖抑制作用,采用Annex-inⅤ-FITC法检测LSC细胞凋亡情况并采用流式细胞术分析细胞周期。结果随着手霉素浓度的增高,LSC细胞增生抑制率明显增高,细胞凋亡率也逐渐增高,且阻滞于G2/M期的细胞比率明显增加。结论手霉素通过阻滞LSC于G2/M期,促进凋亡而抑制其增长,而对正常造血干细胞(HSC)无细胞毒作用。 Objective To probe into the cytotoxic effect of manumycin on leukemic stem cell (LSC).Methods MTT method was used to detect the inhibitory effect of manumycin on LSC proliferation.Annexin Ⅴ-FITC method was adopted to determine LSC apoptosis to analyze cell cycle by flow cytometry.Results With the increase of manumycin concentrations,the inhibitory rate of LSC proliferation had obvious increase,the apoptosis rate also gradually increased,and the cell rate arrested in G2/M phase was significantly enhanced.Conclusions Manumycin could promote apoptosis and inhibit LSC prolieration by arresting LSC in G2/M phase,but has no cytotoxic effect on normal hemopoietic stem cell (HSC).
出处 《中国老年学杂志》 CAS CSCD 北大核心 2010年第16期2257-2258,共2页 Chinese Journal of Gerontology
基金 吉林省科技发展计划项目(20090454)
关键词 法尼基转移酶抑制剂 手霉素 白血病干细胞 细胞增生 细胞凋亡 Farnesyltransferase inhibitors Manumycin Leukemic stem cell (LSC) Cellular proliferation Apoptosis
  • 相关文献

参考文献9

二级参考文献42

  • 1Marley S, Lewis J, Schneider H, et al. Phosphatidylinositol-3 kinase inhibitors reproduce the selective antiproliferative effects of imatinib on chronic myeloid leukaemia progenitor cells. Br J Haematol, 2004, 125(4) :500-511. 被引量:1
  • 2Caraglia M, D'Alessandro AM, Marra M, et al. The farnesyl transferase inhibitor R115777 ( Zarnestra ) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate.Oncogene, 2004,23(41): 6900-6913. 被引量:1
  • 3Rotea WJ, Saad ED. Targeted drugs in oncology: New names,new mechanisms, new paradigm. Am J Health-Syst Pharm,2003,60(12) :1233-1245. 被引量:1
  • 4Beaupre DM, Cepero E, Obeng EA, et al. R115777 induces Rasindependent apoptosis of myeloma cells via multiple intrinsic pathways. Mol Cancer Ther, 2004,3(2) :179-186. 被引量:1
  • 5Van Cutsem E, van de Velde H, Karasek P, et al. Phase Ⅲ trialof gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol, 2004,22 (8):1430-1438. 被引量:1
  • 6Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase I clinicallaboratory correlative trial. Blood, 2001, 97(11): 3361-3369. 被引量:1
  • 7Mo H, Elson CE. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med (Maywood), 2004, 229(7) :567-585. 被引量:1
  • 8Morgan MA, Wegner J, Aydilek E, et al. Synergistic cytotoxiceffects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors.Leukemia, 2003, 17(8): 1508-1520. 被引量:1
  • 9Chun KH, Lee HY, Hassan K, et al. Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells. Cancer Res, 2003,63 (16): 4796-4800. 被引量:1
  • 10Si MS, Ji P, Tromberg BJ, et al. Farnesyltransferase inhibition:a novel method of immunomodulation. Int Immunopharmacol,2003, 3(4): 475-483. 被引量:1

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部